Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma

The prognosis for patients with pediatric high-grade glioma (pHGG) is poor despite aggressive multimodal therapy. Objective responses to targeted therapy with BRAF inhibitors have been reported in some patients with recurrent BRAF-mutant pHGG but are rarely sustained. We performed a retrospective, m...

Full description

Saved in:

Bibliographic Details
Published in:	Neuro-oncology (Charlottesville, Va.) Vol. 24; no. 11; pp. 1964 - 1975
Main Authors:	Rosenberg, Tom, Yeo, Kee Kiat, Mauguen, Audrey, Alexandrescu, Sanda, Prabhu, Sanjay P, Tsai, Jessica W, Malinowski, Seth, Joshirao, Mrinal, Parikh, Karishma, Farouk Sait, Sameer, Rosenblum, Marc K, Benhamida, Jamal K, Michaiel, George, Tran, Hung N, Dahiya, Sonika, Kachurak, Kara, Friedman, Gregory K, Krystal, Julie I, Huang, Michael A, Margol, Ashley S, Wright, Karen D, Aguilera, Dolly, MacDonald, Tobey J, Chi, Susan N, Karajannis, Matthias A
Format:	Journal Article
Language:	English
Published:	England Oxford University Press 02-11-2022
Subjects:	Adolescent Adult Brain Neoplasms - pathology Child Child, Preschool Glioblastoma - drug therapy Glioma - pathology Humans Mitogen-Activated Protein Kinase Kinases Molecular Targeted Therapy Mutation Pediatric Neuro-Oncology Protein Kinase Inhibitors - therapeutic use Proto-Oncogene Proteins B-raf - genetics Retrospective Studies Young Adult targeted therapy BRAF treatment outcome high-grade glioma pediatrics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!